Shenzhen Builds Up R&D Platform For New Combination Drugs
This article was originally published in PharmAsia News
Shenzhen National Biomedical Industry Base recently released its key R&D results at China Hi-Tech Fair. Last March, Shenzhen Ausa Pharmed Co., which has been appointed the new combination drug research center for the biomedical base, received Class I new drug certification from China's State FDA for its enalapril maleate and folic acid tablet. This represents the only new drug with intellectual property rights to obtain such certification in the cardiovascular field in the past three years. Experts observe that innovative drug combination, complemented with expansion of drug indications, may form an effective approach that suits China's situation and helps the nation catch up in the global innovation competition. (Click here for more - Chinese Language)
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.